Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density.

Article Details

Citation

Copy to clipboard

Westenfeld R, Ketteler M, Brandenburg VM

Anti-RANKL therapy--implications for the bone-vascular-axis in CKD? Denosumab in post-menopausal women with low bone mineral density.

Nephrol Dial Transplant. 2006 Aug;21(8):2075-7. Epub 2006 May 15.

PubMed ID

16702197 [ View in PubMed

]

Abstract

Not Available

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Denosumab	Tumor necrosis factor ligand superfamily member 11	Protein	Humans	Yes	Antibody	Details